Table 2.
Top 5 symptoms over 24 mo from baseline by treatment cohort
|
Overall N = 219 |
Dasatinib N = 104 |
Nilotinib N = 82 |
Ponatinib N = 33 |
||||
|---|---|---|---|---|---|---|---|
| Item | Mean (SD) | Item | Mean (SD) | Item | Mean (SD) | Item | Mean (SD) |
| Fatigue | 2.63 (2.57) | Fatigue | 2.39 (2.47) | Fatigue | 2.47 (2.24) | Fatigue | 3.03 (2.89) |
| Drowsiness | 2.08 (2.31) | Drowsiness | 1.80 (2.21) | Disturbed sleep | 2.18 (2.29) | Skin rash | 2.45 (2.73) |
| Disturbed sleep | 2.02 (2.47) | Disturbed sleep | 1.58 (2.30) | Drowsiness | 2.14 (2.17) | Disturbed sleep | 2.37 (2.72) |
| Skin rash | 1.74 (2.35) | Pain | 1.52 (2.36) | Difficulty remembering | 1.78 (1.97) | Drowsiness | 2.34 (2.52) |
| Difficulty remembering | 1.65 (2.03) | Difficulty remembering | 1.65 (1.95) | Skin rash | 1.57 (2.24) | Dry mouth | 2.29 (2.85) |
| Inference with life | |||||||
| WAW | 1.5 (2.13) | WAW | 1.37 (2.01) | WAW | 1.16 (1.82) | WAW | 1.94 (2.44) |
| REM | 1.28 (1.84) | REM | 1.05 (1.7) | REM | 0.95 (1.36) | REM | 1.83 (2.21) |
Longitudinal analysis: REM, relations with others, enjoyment of life, and mood; SD, standard deviation; WAW, working with others, general activity, and walking.
Overall top 5 symptoms for all patients combined are represented in column 1. The next three columns represent the top 5 symptoms for each cohort, separately.